{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:18:48Z","timestamp":1787987928622,"version":"build-2784847793"},"reference-count":29,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie (United States)","doi-asserted-by":"publisher","award":["B20-320"],"award-info":[{"award-number":["B20-320"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: We evaluated the risk of acute anterior uveitis (AAU) in patients with ankylosing spondylitis (AS) during treatment with tumor necrosis factor-alpha inhibitors (TNFis). Methods: This study was performed on AS patients using the Korean National Health Insurance claims database. We analyzed the first and total occurrence of AAU during the first 2 years of TNFis use according to the type of TNFis. Additionally, the occurrence of AAU was assessed in subgroups with or without prior AAU before TNFis initiation. Results: In total, 5938 AS patients initiated TNFis use between 2009 and 2017 and used them for more than 2 years. Among them, 1488 (25.1%) patients had a history of AAU before starting TNFis treatment. Compared to adalimumab, the use of etanercept (hazard ratio [HR] 1.77) increased the risk of AAU. The incidence rate ratio (IRR) of AAU with etanercept was significantly higher than that of adalimumab (IRR 1.78). The IRR of AAU was also higher for etanercept than adalimumab use in patients with (IRR 1.86) and without (IRR 2.92) a history of AAU. Conclusion: These data suggest that compared to anti-TNF-alpha monoclonal antibodies, etanercept has a higher incidence of AAU regardless of a history of AAU.<\/jats:p>","DOI":"10.3390\/jcm11030631","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T11:02:53Z","timestamp":1643194973000},"page":"631","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Risk of Acute Anterior Uveitis in Ankylosing Spondylitis According to the Type of Tumor Necrosis Factor-Alpha Inhibitor and History of Uveitis: A Nationwide Population-Based Study"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9213-9768","authenticated-orcid":false,"given":"Soo Min","family":"Ahn","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minju","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3307-2970","authenticated-orcid":false,"given":"Ye-Jee","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusun","family":"Lee","sequence":"additional","affiliation":[{"name":"AbbVie Pty, Ltd., Seoul 06182, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8029-7355","authenticated-orcid":false,"given":"Yong-Gil","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing Spondylitis and Axial Spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","article-title":"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: A systematic review and meta-analysis","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","first-page":"478","article-title":"Impact of Uveitis on Quality of Life: A Prospective Study from a Tertiary Referral Rheumatology-Ophthalmology Collaborative Uveitis Center in Italy","volume":"19","author":"Fabiani","year":"2017","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/intimm\/dxu102","article-title":"Anti-TNF therapy: Past, present and future","volume":"27","author":"Monaco","year":"2014","journal-title":"Int. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1185\/03007995.2014.969368","article-title":"Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: An analysis of a large US claims database","volume":"30","author":"Wendling","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wu, D., Guo, Y.-Y., Xu, N.-N., Zhao, S., Hou, L.-X., Jiao, T., and Zhang, N. (2015). Efficacy of anti\u2013tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: A meta\u2013analysis. BMC Musculoskelet. Disord., 16.","DOI":"10.1186\/s12891-015-0489-2"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2016-210931","article-title":"Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: Results from the Swedish biologics register","volume":"76","author":"Lie","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13075-020-02187-y","article-title":"Occurrence of anterior uveitis in patients with spondyloarthritis treated with tumor necrosis factor inhibitors: Comparing the soluble receptor to monoclonal antibodies in a large observational cohort","volume":"22","author":"Khoury","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","article-title":"Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data","volume":"32","author":"Kim","year":"2017","journal-title":"J. Korean Med. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3904\/kjim.2019.144","article-title":"Pregnancy outcomes in Korean women with ankylosing spondylitis","volume":"36","author":"Park","year":"2021","journal-title":"Korean J. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"Valkenburg","year":"1984","journal-title":"Arthritis Rheum."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Standardization of Uveitis Nomenclature for Reporting Clinical Data (2005). Results of the First International Workshop. Am. J. Ophthalmol., 140, 509\u2013516.","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ajo.2017.03.029","article-title":"Randomized Controlled Trial Evaluating a Standardized Strategy for Uveitis Etiologic Diagnosis (ULISSE)","volume":"178","author":"Kodjikian","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/acr.21616","article-title":"Prevalence and factors associated with uveitis in spondylarthritis patients in France: Results from an observational survey","volume":"64","author":"Lekpa","year":"2012","journal-title":"Arthritis Care Res."},{"key":"ref_18","first-page":"CD005468","article-title":"TNF-alpha inhibitors for ankylosing spondylitis","volume":"4","author":"Maxwell","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0014-4835(05)80017-X","article-title":"Systemic anti-tumor necrosis factor antibody treatment exacerbates endotoxin-induced uveitis in the rat","volume":"61","author":"Verhagen","year":"1995","journal-title":"Exp. Eye Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3109\/02713683.2010.486520","article-title":"Anti-TNF-alpha treatment: A possible promoter in endogenous uveitis? Observational report on six patients: Occurrence of uveitis following etanercept treatment","volume":"35","author":"Kakkassery","year":"2010","journal-title":"Curr. Eye Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ajo.2016.07.016","article-title":"Anti-TNFalpha Treatment for HLA-B27-Positive Ankylosing Spondylitis-Related Uveitis","volume":"170","author":"Kim","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/ard.2006.052092","article-title":"Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: A retrospective study","volume":"65","author":"Guignard","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1007\/s10067-016-3426-3","article-title":"Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: State of the art","volume":"35","author":"Fabiani","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/bjo.87.7.925","article-title":"Does etanercept induce uveitis?","volume":"87","author":"Reddy","year":"2003","journal-title":"Br. J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"471319","DOI":"10.1155\/2014\/471319","article-title":"Inefficacy or paradoxical effect? Uveitis in ankylosing spondylitis treated with etanercept","volume":"2014","author":"Raffeiner","year":"2014","journal-title":"Case Rep. Med."},{"key":"ref_26","first-page":"1132","article-title":"Uveitis occurrence in patients with ankylosing spondylitis according to the type of tumour necrosis factor inhibitor: A cohort study of 175 patients","volume":"38","author":"Choi","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.semarthrit.2006.02.001","article-title":"Tumor Necrosis Factor Antagonists: Different Kinetics and\/or Mechanisms of Action May Explain Differences in the Risk for Developing Granulomatous Infection","volume":"36","author":"Furst","year":"2006","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12348-020-00202-6","article-title":"A review of ocular adverse events of biological anti-TNF drugs","volume":"10","author":"Pavesio","year":"2020","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/3\/631\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:08:26Z","timestamp":1760134106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/3\/631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["jcm11030631"],"URL":"https:\/\/doi.org\/10.3390\/jcm11030631","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,26]]}}}